Comparison of 8 weeks’ outcomes between patients who received FMT-AID versus those who received optimised SMT
| FMT-AID (n=35) | SMT (n=31) | P value | OR (95% CI) | |
| Clinical | ||||
| Clinical response at 8 weeks | 23 (65.7) | 11 (35.5) | 0.014 | 3.5 (1.3 to 9.6) |
| Clinical remission 8 weeks | 21 (60) | 10 (32.3) | 0.02 | 3.2 (1.1 to 8.7) |
| Endoscopic | ||||
| Endoscopic response 8 weeks | 17/33 (51.5) | 4/23 (17.4) | 0.012 | 5.0 (1.4 to 18.1) |
| Endoscopic remission 8 weeks | 12/33 (36.4) | 4/23 (17.4) | 0.15 | 2.7 (0.7 to 9.8) |
| Composite | ||||
| Deep remission 8 weeks | 12/33 (36.4) | 2/23 (8.7) | 0.03 | 6.0 (1.2 to 30.2) |
| Clinical remission and endoscopic response 8 weeks | 17/33 (51.5) | 2/23 (8.7) | 0.001 | 11.1 (2.2 to 55.4) |
| Biomarker | ||||
| Faecal calprotectin, µg/g, median (IQR) at 8 weeks | 25.7 (22–45) | 30.1 (16–256) | 0.95 | |
| Delta FCP, µg/g, median (IQR) at 8 weeks | 274.7 (181–435) | 173.4 (97–384) | 0.16 | |
| FCP <50 µg/g at 8 weeks, n (%) | 17/20 (85%) | 6/10 (60%) | 0.13 | 3.8 (0.6 to 22.0) |
Numbers in bracket indicate percentage.
FMT-AID, faecal microbiota transplantation and anti-inflammatory diet; SMT, standard medical therapy.